• 咨询热线
    客服服务热线 13671568941/15317326293
  • 在线咨询
  • 微信客服
    微信客服
  • 公众号
    扫码关注公众号

GSK-1070916

CAS No. 942918-07-2

GSK-1070916 ( GSK1070916 | GSK 1070916 )

产品货号. M16749 CAS No. 942918-07-2

Aurora B 和 C 的有效、选择性和 ATP 竞争性抑制剂,Ki 分别为 0.38 nM 和 1.5 nM。

纯度: >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
规格 价格/人民币 库存 数量
5MG ¥778 有现货
10MG ¥1312 有现货
25MG ¥2252 有现货
50MG ¥3540 有现货
100MG ¥5249 有现货
200MG 获取报价 有现货
500MG 获取报价 有现货
1G 获取报价 有现货

生物学信息

  • 产品名称
    GSK-1070916
  • 注意事项
    本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
  • 产品简述
    Aurora B 和 C 的有效、选择性和 ATP 竞争性抑制剂,Ki 分别为 0.38 nM 和 1.5 nM。
  • 产品描述
    A potent, selective and ATP-competitive inhibitor of Aurora B and C with Ki of 0.38 nM and 1.5 nM, respectively; displays >250-fold selectivity over Aurora A; shows potent antiproliferative effect (EC50=7 nM) in A549 human lung cancer cells; causes inhibition of histone H3 phosphorylation at serine 10 in human colon cancer (Colo205) and tumor regression in human leukemia (HL-60) in mice.Ovarian Cancer Phase 2 Clinical.
  • 体外实验
    GSK-1070916 potently inhibits Aurora B/INCENP and Aurora C/INCENP kinases with Kis of 0.38±0.29 and 1.45±0.35 nM, respectively, but is less potent against Aurora A/ TPX2 with a Ki of 492±61 nM. GSK-1070916 also inhibits FLT1, TIE2, SIK, FLT4, and FGFR1 with IC50 values of 42, 59, 70, 74, and 78 nM, respectively. Treatment of A549 human lung cancer cells with GSK-1070916 results in a potent antiproliferative effect (EC50=7 nM). GSK-1070916 inhibits a panel of tumor cell lines and is shown o inhibits the phosphorylation of HH3- S10 in all cell lines with average EC50 values ranging from 8 to 118 nM.
  • 体内实验
    In nude mice implanted with human colon tumor (HCT116) xenografts, a single dose of GSK-1070916 administered i.p. inhibits HH3-S10 phosphorylation in a dose-dependent manner. Repeated i.p. administration of GSK-1070916 produces complete or partial antitumor activity in 4 of 8 tumor types [lung, A549; colon, HCT116; acute myelogenous leukemia (AML), HL60; and chronic myelogenous leukemia, K562], stable disease in 3 of 8 (colon, Colo205; lung, H460; and breast, MCF-7), and tumor growth delay in 1 of 8 tumor types (colon, SW620). Daily administration of GSK-1070916 is generally well-tolerated.
  • 同义词
    GSK1070916 | GSK 1070916
  • 通路
    Cell Cycle/DNA Damage
  • 靶点
    Aurora Kinase
  • 受体
    SIK| Aurora B-INCENP| Aurora C-INCENP| FLT1| Tie-2
  • 研究领域
    Cancer
  • 适应症
    Ovarian Cancer

化学信息

  • CAS Number
    942918-07-2
  • 分子量
    507.6293
  • 分子式
    C30H33N7O
  • 纯度
    >98% (HPLC)
  • 溶解度
    DMSO: ≥ 26.5 mg/mL
  • SMILES
    O=C(NC1=CC=C(C2=NN(CC)C=C2C3=C4C(NC(C5=CC=CC(CN(C)C)=C5)=C4)=NC=C3)C=C1)N(C)C
  • 化学全称
    Urea, N'-[4-[4-[2-[3-[(dimethylamino)methyl]phenyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]-1-ethyl-1H-pyrazol-3-yl]phenyl]-N,N-dimethyl-

运输与储存

  • 储存条件
    (-20℃)
  • 运输条件
    With Ice Pack
  • 稳定性
    ≥ 2 years

参考文献

1. Adams ND, et al. J Med Chem. 2010 May 27;53(10):3973-4001. 2. Hardwicke MA, et al. Mol Cancer Ther. 2009 Jul;8(7):1808-17. 3. Moy C, et al. J Transl Med. 2011 Jul 15;9:110.
产品手册
关联产品
  • MLN8054

    一种有效的、选择性的、ATP 竞争性的、口服活性的 Aurora A 激酶抑制剂,IC50 为 4 nM。

  • Phthalazinone pyrazo...

    Phthalazinonepyrazol 是一种有效的、选择性的、口服生物可利用的 Aurora-A 激酶抑制剂。 Aurora-A 在多种肿瘤类型中过度表达并表现出致癌活性。

  • Aurora Kinase Inhibi...

    Aurora 激酶抑制剂 III 是 Aurora A 激酶的有效抑制剂 (IC50 = 42 nM)。1 它对 Aurora A 的选择性高于 BMX、BTK、IGF-1R、c-Src、TRKB、SYK 和 EGFR。